Is marriage linked to dementia? New study explains
Contrary to popular belief, marriage may be linked to a higher risk of dementia in older age in the United States, according to a new study by researchers at Florida State University, US.
The study, led by Selin Karakose and colleagues, tracked over 24,000 Americans with an average age of 72 for up to 18 years. Participants were divided into four groups: married, widowed, divorced, and never married.
'Unmarried individuals may have a lower risk of dementia compared to married adults,' the study's authors wrote. After adjusting for age and gender, the findings revealed that those who had never married were 40% less likely to develop dementia than married individuals. Widowed participants had a 27% lower risk, and divorced individuals had a 34% lower risk.
The results challenge previous research suggesting marriage offers protective benefits against cognitive decline. Earlier studies linked marriage to stronger immune systems, reduced stress, and greater social support—all factors thought to guard against dementia.
However, the new research, published in the journal Alzheimer's & Dementia, turns this assumption on its head. 'Contrary to expectations and challenging the commonly held belief that marriage is protective against cognitive decline and dementia, this study found that married older adults exhibited a higher risk of dementia compared to those never married, divorced, and widowed,' an expert commented.
The study does not offer a definitive explanation for the trend. Researchers suggest possible factors, such as smaller social networks among married individuals, increased caregiving-related stress, or delayed dementia diagnosis in unmarried people.
The authors cautioned that the study does not imply all married individuals are destined to develop dementia. Rather, it highlights that the relationship between marriage and cognitive health is complex and warrants further research.
Experts advise individuals to focus on building strong, supportive relationships and maintaining a healthy, low-stress lifestyle, regardless of marital status, to promote better brain health in later life.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
3 hours ago
- Business Recorder
Dow briefly hits record high on UnitedHealth's gains; data in focus
The blue-chip Dow briefly hit a record high on Friday, as UnitedHealth's shares jumped after Berkshire Hathaway raised its stake in the health insurer, while investors assessed mixed data to gauge the Federal Reserve's monetary policy path this year. UnitedHealth Group gained 11.6% to hit a more than two-month high after Warren Buffett's company revealed a new investment in the health insurer, while Michael Burry's Scion Asset Management also turned more bullish on the company. Rising costs in the broader healthcare sector and an about 40% slump in heavyweight UnitedHealth's shares this year have left the Dow lagging its Wall Street peers on the road to record highs. The price-weighted index last scaled an all-time high on December 4. This week, however, the healthcare sector is the top performer on the S&P 500 and is on track for its best weekly performance since October 2022. Other insurance stocks Centene and Molina gained 5.2% each. A report showed retail sales in July rose as expected, but the University of Michigan's index tracking consumer confidence fell more than expected to 58 as inflation expectations rise. 'As long as consumer spending holds up and companies are able to retain workers because of that robust spending, the flywheel can continue to spin, pushing corporate profits and stock prices higher,' said Chris Zaccarelli, chief investment officer for Northlight Asset Management, speaking on the retail sales figures. At 10:11 a.m. ET, the Dow Jones Industrial Average rose 99.11 points, or 0.22%, to 45,011.45, the S&P 500 lost 7.39 points, or 0.11%, to 6,461.15 and the Nasdaq Composite lost 30.70 points, or 0.14%, to 21,681.10. Wall Street's main U.S. stock indexes are on track for their second week of gains, buoyed by expectations that the Fed could restart its monetary policy easing cycle with a 25-basis-point interest rate cut in September. The central bank last lowered borrowing costs in December and said U.S. tariffs could add to price pressures. However, recent labor market weakness and signs that tariff-induced inflation was yet to reflect in headline consumer prices have made investors confident of a potential dovish move next month. Still, Chicago Fed President Austan Goolsbee said recent data reports showed a stagflationary impulse from tariffs on the economy. On the trade front, U.S. President Donald Trump said he would unveil tariffs on steel and semiconductors next week. Applied Materials tumbled 11.3% after the chip equipment maker issued weak fourth-quarter forecasts. Intel rose 3% after a report said the Trump administration was in talks for the U.S. government to potentially take a stake in the chipmaker. Attention was also on a meeting between Trump and Russian counterpart Vladimir Putin that markets hope could pave the way for a resolution to the Ukraine conflict. The meeting will take place at 1900 GMT. Declining issues outnumbered advancers by a 1.22-to-1 ratio on the NYSE and a 1.31-to-1 ratio on the Nasdaq. The S&P 500 posted 8 new 52-week highs and no new lows while the Nasdaq Composite recorded 52 new highs and 45 new lows.
Business Recorder
22-07-2025
- Business Recorder
AstraZeneca says to invest $50bn in the US
LONDON: British pharmaceutical giant AstraZeneca said Tuesday it would invest $50 billion in the United States amid a looming deadline of ramped-up tariffs from Washington. A large chunk of the funds will go toward building a multi-billion-dollar manufacturing centre in Virginia, the company said in a statement, adding that it expects 50 percent of its revenue to come from the United States by 2030. 'Today's announcement underpins our belief in America's innovation in biopharmaceuticals,' the statement quoted CEO Pascal Soriot as saying. US President Donald Trump has opened the door to potential tariffs targeting pharmaceuticals, which have so far benefited from exemptions to his sweeping levies on imports from trading partners. He ordered an investigation launched into pharmaceutical imports, suggesting that levies could reach up to 200 percent. AstraZeneca to buy EsoBiotec for up to $1 billion The United States is a key market for the pharmaceutical industry, and AstraZeneca had already announced in April that it had begun transferring part of its European production to the United States. 'For decades Americans have been reliant on foreign supply of key pharmaceutical products,' US Commerce Secretary Howard Lutnick said in a statement. He added that the new tariffs are focused on 'ending this structural weakness'. The announcement included a new factory in Virginia, which will be the company's 'largest single manufacturing investment'. Other major pharmaceutical companies, which had been exempt from tariffs for 30 years, have, in recent months, begun shifting investment and production to the United States.
Express Tribune
19-07-2025
- Express Tribune
Trump pulls US from WHO pandemic reforms
President Donald Trump's administration said Friday the United States was rejecting changes agreed last year for the World Health Organization on its pandemic response, saying they violated US sovereignty. Trump on returning to office on January 20 immediately began the withdrawal of the United States from the UN body, but the State Department said the language from last year would still have been binding on the United States. Secretary of State Marco Rubio and Health and Human Services Secretary Robert F. Kennedy, who is a longtime critic of vaccines, said that the changes "risk unwarranted interference with our national sovereign right to make health policy." "We will put Americans first in all our actions and we will not tolerate international policies that infringe on Americans' speech, privacy or personal liberties," they said in a joint statement.
